000178088 001__ 178088
000178088 005__ 20240229133759.0
000178088 0247_ $$2doi$$a10.1002/jcsm.12871
000178088 0247_ $$2pmid$$apmid:34898035
000178088 0247_ $$2ISSN$$a2190-5991
000178088 0247_ $$2ISSN$$a2190-6009
000178088 0247_ $$2altmetric$$aaltmetric:118915789
000178088 037__ $$aDKFZ-2021-03095
000178088 041__ $$aEnglish
000178088 082__ $$a610
000178088 1001_ $$aMaurus, Johannes$$b0
000178088 245__ $$aValidation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairments.
000178088 260__ $$aHoboken, NJ$$bWiley$$c2022
000178088 3367_ $$2DRIVER$$aarticle
000178088 3367_ $$2DataCite$$aOutput Types/Journal article
000178088 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1644586542_8053
000178088 3367_ $$2BibTeX$$aARTICLE
000178088 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178088 3367_ $$00$$2EndNote$$aJournal Article
000178088 500__ $$aVolume13, Issue1, February 2022, Pages 264-275
000178088 520__ $$aThe strength, assistance walking, rise from a chair, climb stairs, and falls (SARC-F) questionnaire is a well-established instrument for screening of sarcopenia and sarcopenia-related functional impairments. As it is based on self-reporting, its use precludes patients who are unable to answer the questionnaire as a consequence of severe acute diseases or cognitive impairment. Therefore, we aimed to validate a proxy-reported version of the SARC-F for both ad-hoc as well as retrospective screening for severe sarcopenia-related functional impairments.Patients aged ≥60 years completed the SARC-F and performed the short physical performance battery (SPPB) at baseline (T1). Proxies in Cohort A gave a simultaneous assessment of the patients' functional status with the proxy-reported SARC-F at T1 and again, retrospectively, after 3 months (T2). Proxies in Cohort B only completed the SARC-F retrospectively at T2. The questionnaires' performances were assessed through sensitivity/specificity analyses and receiver operating characteristic (ROC) curves. For non-inferiority analyses, results of both the patient-reported and proxy-reported SARC-F were correlated with the SPPB total score as well as the results of the chair-rise test subcategory; the respective correlation coefficients were tested against each other.One hundred and four patients and 135 proxies participated. Using a SPPB score < 9 points as the reference standard, the proxy-reported SARC-F identified patients at high risk for sarcopenia-related functional impairment with a sensitivity of 0.81 (ad-hoc), 0.88 (retrospective Cohort A), and 0.87 (retrospective Cohort B) as well as a specificity of 0.89 (ad-hoc), 0.78 (retrospective Cohort A), and 0.64 (retrospective Cohort B). Areas under the ROC curves were ≥ 0.9 for the ad-hoc proxy-reported SARC-F and the retrospective proxy-reported SARC-F in both cohorts. The proxy-reported SARC-F showed a non-inferior correlation with the SPPB compared with the patient-reported SARC-F for ad-hoc (P = <0.001) as well as retrospective screening for severe sarcopenia-related functional impairment in both Cohorts A (P = 0.007) and B (P = 0.026).Proxy-reported SARC-F is a valid instrument for both ad-hoc as well as retrospective screening for sarcopenia-related functional impairment and could become the standard tool for evaluating this risk in older adults with severe acute disease, for example, in patients with quickly evolving haematological conditions.
000178088 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000178088 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178088 650_7 $$2Other$$aPatient-reported outcome
000178088 650_7 $$2Other$$aPremorbid condition
000178088 650_7 $$2Other$$aProxy-reported outcome
000178088 650_7 $$2Other$$aSARC-F
000178088 650_7 $$2Other$$aSarcopenia
000178088 650_7 $$2Other$$aSarcopenia-related functional impairments
000178088 7001_ $$0P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e$$aTerzer, Tobias$$b1$$udkfz
000178088 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b2$$udkfz
000178088 7001_ $$aGoisser, Sabine$$b3
000178088 7001_ $$aEidam, Annette$$b4
000178088 7001_ $$aRoth, Anja$$b5
000178088 7001_ $$aJanssen, Maike$$b6
000178088 7001_ $$aJaramillo, Sonia$$b7
000178088 7001_ $$aLorenz, Hannes Martin$$b8
000178088 7001_ $$aMicol, William$$b9
000178088 7001_ $$aHauer, Klaus$$b10
000178088 7001_ $$aMüller-Tidow, Carsten$$b11
000178088 7001_ $$aBauer, Jürgen M$$b12
000178088 7001_ $$aJordan, Karin$$b13
000178088 7001_ $$00000-0001-8518-3616$$aNeuendorff, Nina Rosa$$b14
000178088 773__ $$0PERI:(DE-600)2586864-0$$a10.1002/jcsm.12871$$gp. jcsm.12871$$n1$$p264-275$$tJournal of cachexia, sarcopenia and muscle$$v13$$x2190-5991$$y2022
000178088 909CO $$ooai:inrepo02.dkfz.de:178088$$pVDB
000178088 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178088 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000178088 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000178088 9141_ $$y2021
000178088 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2021-02-03
000178088 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000178088 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000178088 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-03
000178088 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-03
000178088 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-03
000178088 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CACHEXIA SARCOPENI : 2021$$d2022-11-18
000178088 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000178088 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000178088 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:28Z
000178088 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:28Z
000178088 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-04-16T15:13:28Z
000178088 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000178088 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000178088 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ CACHEXIA SARCOPENI : 2021$$d2022-11-18
000178088 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000178088 980__ $$ajournal
000178088 980__ $$aVDB
000178088 980__ $$aI:(DE-He78)C060-20160331
000178088 980__ $$aUNRESTRICTED